Sudden Cardiac Death in Systemic Right Ventricle

Overview

In complete transposition of the great arteries (TGA) with previous atrial switch repair, and congenitally corrected transposition of the great arteries (ccTGA), the morphological right ventricle and its tricuspid valve continue to support the systemic circulation. This results in late complications including including sudden death. This retrospective multicentric study aims to evaluate the prevalence of SCD in a contemporary population of patients with a systemic RV and identify specific risk factors for SCD and hemodynamically significant ventricular arrhythmia This registry records demographics, clinical, imaging data, electrophysiological and laboratory of patients with a sRV and a transposition of the great arteries Primary end points are defined by sudden cardiac death, near-miss sudden death, as well as sustained VT requiring defibrillation.

1 Registry design The registry is a retrospective multicentric registry that involves the collection of demographics, clinical, imaging data, electrophysiological and laboratory of patients with a sRV and a transposition of the great arteries (TGA or ccTGA). Ethical or research committee approval should be obtained in each contributing center and all data will be collected retrospectively. A minimum of 900 patients are expected to be registered. Patient population Inclusion criteria: patients \>16 years of age with a sRV and a transposition of the great arteries (TGA or ccTGA) with "two-ventricle circulation" under active follow-up between 2000 and 2018. Exclusion criteria: CHD with univentricular heart physiology 2\. Registry procedures 1. Design Data on all adult patients (\>16 years of age) with sRV under active follow-up between January 1, 2000 and September 30, 2018 will be recorded. Baseline data, as well data of the last follow-up recorded during this period will be used. Parameters are chosen for inclusion in data collection on the basis of a review of sRV literature on single predictors of outcome The patients' medical records will be reviewed to collect demographic information, medical and surgical details The chosen parameters of patient past medical history to record include: * Type of TGA, TGA complexity, type of surgery, age at surgery, reoperation * Cardio-vascular events such as atrial arrhythmia, heart failure, pacemaker implantation * Performing electrophysiologic exploration and its results: normal or inducible sustained VT/VF, sinus node dysfunction, atrioventricular node dysfunction * 24H Holter ECG finding: sinus node disease, atrial arrhythmia, non-sustained VT, sustained VT * Notion of complete pregnancy (\> 20 weeks of gestation) Baseline data will be taken at the first assessment as an adult (\> 16 years old). They include variables from clinical status, 12-lead ECG, transthoracic echocardiography, CMR (if available), cardiopulmonary exercise test, and laboratory tests (if available). Detailed data are: * Clinical status: NYHA function class, syncope and palpitations. * Cardiac treatment * Electrocardiographic parameters, including rhythm assessment, heart rate, QRS duration, and QT interval manually collected * Echocardiographic parameters with visual sRVEF, tricuspid regurgitation grade, presence of pulmonary stenosis and baffle stenosis or leak. Only transthoracic echocardiography performed by experienced operators will be considered. * Measurements of oxygen consumption (VO2) during exercise test: peak oxygen consumption, VE/VCO2, peak blood pressure and peak heart rate. * If available, cardiac magnetic resonance imaging parameters, such as sRV volumes, sRV mass, sRVEF and presence of late gadolinium enhancement lesions. * If available, brain natriuretic peptide, with normal ranges provided by centers. Vital status at late follow-up during the study period (up to September 30, 2018) will be retrieved from national databases or patients' general practitioner records. Cardiac events such as heart failure, atrial arrhythmia, sustained ventricular tachycardia, death and cause of death will be reported. 2. Preservation and confidentiality of registry records Data collected at each investigational site will be entered in a local database. In this database, patient will be identifiable only by the investigator of the site. The data will be anonymized via the use of a unique number. This one will be created by a secure process called the function of occultation of the nominative information (FOIN). It will be impossible to find the identity of a patient from this number (irreversibility of encryption). The data will be anonymously transmitted to the main investigational site (Inserm U970, Paris Cardiovascular Research Center, Hôpital Européen Georges Pompidou Paris, France). The data will be stored on a computer server dedicated only to the storage and processing of the project data. The computer used for the analyzes is in a locked room within the secure premises of the European Georges Pompidou Hospital ( INSERM U970, Cardiovascular Research Center of Paris), guarded 24/24 with access by name badge. Persons having direct access (for example, investigators, persons in charge of quality control, Clinical Research Assistants, and all persons involved in the study) take all necessary precautions to ensure the confidentiality of information relating to the persons who are suitable for it. All the co-investigators will have access to the data of the study to develop their working hypotheses within the premises of the INSERM U970, but no data can be transferred outside the dedicated and secure computer server. European George Pompidou Hospital as sponsor is subject to the rights and obligations as 'data controller' set forth under the General Data Protection Regulation 2016/679 ("GDPR") in relation to the processing of personal data in accordance with the protocol. Participating site is subject to the rights and obligations as 'data processor' set forth under the GDPR in relation to the processing of personal data in accordance with the protocol. Sponsor and participating site agree that such data: (a) is to be used only for the purposes as described in the protocol; (b) will not be used for commercial purposes and (c) will not be transferred to a third party. Sponsor and participating site shall provide sufficient safeguards in respect of the administrative, technical and organizational measures for processing personal data and take all necessary measures to protect the confidentiality, privacy and prevention from accidental or unauthorized destruction, accidental loss, as well as from alteration, access and any other unauthorized processing of the data. Participating site shall promptly inform Sponsor of any security breach, reasonably assist Sponsor with the handling of (a) responses to any security breach and (b) any requests from data subjects under Chapter III of the GDPR. The Participating site shall obtain prior specific or general written consent from Sponsor before engaging a subprocessor of the Personal Data. Participating site remains data controller of the data contained in its patients' medical records for the purposes of providing medical care to its patients and for other academic research purposes initiated by participating site. 3\. Quality assurance: 1. Verification of data: Source data will be verified by comparing the data to medical records and case report forms in the form of a random sample. 2. Clinical events committee: To avoid or minimize bias, an independent clinical events committee at the main investigational site, consisting of independent physicians, assesses all primary endpoint clinical events.